TCR-T Oncology Pipeline

About Anocca

Anocca is a private, pre-clinical stage biotech developing next-generation TCR-T cell therapies for cancer. The company has built a proprietary, integrated platform that systematically decodes T-cell biology to identify cancer-selective HLA-peptide targets and match them with optimal T-cell receptors. By focusing on the vast intracellular target space, Anocca aims to address limitations of first-generation cell therapies like CAR-T and create precision treatments for a broader range of solid and hematological cancers. Its approach combines novel engineered cell systems, high-throughput biology, and custom software analytics.

Therapeutic Areas